サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413074

重症筋無力症治療薬市場：タイプ別、エンドユーザー別-2024-2030年の世界予測

Myasthenia Gravis Treatment Market by Type (Medication, Surgery), End-User (Clinics, Hospitals) - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 199 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
重症筋無力症治療薬市場：タイプ別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 199 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

重症筋無力症治療薬市場規模は2023年に19億3,000万米ドルと推計され、2024年には20億米ドルに達し、CAGR 5.21%で2030年には27億6,000万米ドルに達すると予測されます。

重症筋無力症治療薬の世界市場

主な市場の統計
基準年[2023］ 19億3,000万米ドル
予測年[2024］ 20億米ドル
予測年 [2030] 27億6,000万米ドル
CAGR（%） 5.21%
重症筋無力症治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは重症筋無力症治療薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、重症筋無力症治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-重症筋無力症治療薬市場の市場規模および予測は？

2-重症筋無力症治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-重症筋無力症治療薬市場における技術動向と規制の枠組みは？

4-重症筋無力症治療薬市場における主要ベンダーの市場シェアは？

5-重症筋無力症治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で高齢者人口が増加
      • 重症筋無力症による目の腫れの症例が増加
      • 治療のための臨床試験が増加
    • 抑制要因
      • 治療に伴う高額な費用
    • 機会
      • ヘルスケアインフラの改善
      • 医薬品開発のパイプライン研究数の急増
    • 課題
      • 薬に伴う副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 重症筋無力症治療薬市場：タイプ別

  • 薬
  • 手術

第7章 重症筋無力症治療薬市場：エンドユーザー別

  • クリニック
  • 病院

第8章 南北アメリカの重症筋無力症治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の重症筋無力症治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの重症筋無力症治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Alexion Pharmaceutical Inc.
    • Argenx
    • Avadel Pharmaceuticals, PLC
    • Bausch Health Companies Inc.
    • Catalyst Pharmaceuticals Inc.
    • CSL Behring AG
    • F.Hoffmann-La Roche AG
    • GlaxoSmithKline PLC
    • Mitsubishi Tanabe Pharma Corporation
    • Pfizer, Inc.
    • Sandoz Inc. by Novartis AG
    • Sun Pharmaceuticals Industries
    • Taj Pharmaceuticals Ltd.
    • Takeda Pharmaceuticals Company Limited
    • Troikaa Pharmaceuticals Ltd.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. MYASTHENIA GRAVIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MYASTHENIA GRAVIS TREATMENT MARKET DYNAMICS
  • FIGURE 7. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. MYASTHENIA GRAVIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 9. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. ARGENTINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 16. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. BRAZIL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. CANADA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. MEXICO MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 25. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AUSTRALIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CHINA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. INDIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. INDONESIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDONESIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. JAPAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MALAYSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MALAYSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. PHILIPPINES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. PHILIPPINES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. SINGAPORE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. SINGAPORE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SOUTH KOREA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. TAIWAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. TAIWAN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. THAILAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. THAILAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. VIETNAM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. VIETNAM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. DENMARK MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. EGYPT MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. FINLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FRANCE MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. GERMANY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. ISRAEL MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ITALY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. NETHERLANDS MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NIGERIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NORWAY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. POLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. QATAR MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. RUSSIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SAUDI ARABIA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH AFRICA MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SPAIN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SWEDEN MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWITZERLAND MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. TURKEY MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED ARAB EMIRATES MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED KINGDOM MYASTHENIA GRAVIS TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. MYASTHENIA GRAVIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 98. MYASTHENIA GRAVIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 99. MYASTHENIA GRAVIS TREATMENT MARKET LICENSE & PRICING
目次
Product Code: MRR-0A609A26A9CC

[199 Pages Report] The Myasthenia Gravis Treatment Market size was estimated at USD 1.93 billion in 2023 and expected to reach USD 2.00 billion in 2024, at a CAGR 5.21% to reach USD 2.76 billion by 2030.

Global Myasthenia Gravis Treatment Market

KEY MARKET STATISTICS
Base Year [2023] USD 1.93 billion
Estimated Year [2024] USD 2.00 billion
Forecast Year [2030] USD 2.76 billion
CAGR (%) 5.21%
Myasthenia Gravis Treatment Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Myasthenia Gravis Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Myasthenia Gravis Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Myasthenia Gravis Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alexion Pharmaceutical Inc., Argenx, Avadel Pharmaceuticals, PLC, Bausch Health Companies Inc., Catalyst Pharmaceuticals Inc., CSL Behring AG, F.Hoffmann-La Roche AG, GlaxoSmithKline PLC, Mitsubishi Tanabe Pharma Corporation, Pfizer, Inc., Sandoz Inc. by Novartis AG, Sun Pharmaceuticals Industries, Taj Pharmaceuticals Ltd., Takeda Pharmaceuticals Company Limited, and Troikaa Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Myasthenia Gravis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Medication
    • Surgery
  • End-User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Myasthenia Gravis Treatment Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Myasthenia Gravis Treatment Market?

3. What are the technology trends and regulatory frameworks in the Myasthenia Gravis Treatment Market?

4. What is the market share of the leading vendors in the Myasthenia Gravis Treatment Market?

5. Which modes and strategic moves are suitable for entering the Myasthenia Gravis Treatment Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Myasthenia Gravis Treatment Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population across the globe
      • 5.1.1.2. Increasing cases of swollen eyes due to Myasthenia Gravis
      • 5.1.1.3. Rising clinical trials for treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Improving healthcare infrastructure
      • 5.1.3.2. Upsurge in the number of pipeline studies for drug development
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Myasthenia Gravis Treatment Market, by Type

  • 6.1. Introduction
  • 6.2. Medication
  • 6.3. Surgery

7. Myasthenia Gravis Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Hospitals

8. Americas Myasthenia Gravis Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Myasthenia Gravis Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Myasthenia Gravis Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. AbbVie Inc.
    • 12.1.2. Alexion Pharmaceutical Inc.
    • 12.1.3. Argenx
    • 12.1.4. Avadel Pharmaceuticals, PLC
    • 12.1.5. Bausch Health Companies Inc.
    • 12.1.6. Catalyst Pharmaceuticals Inc.
    • 12.1.7. CSL Behring AG
    • 12.1.8. F.Hoffmann-La Roche AG
    • 12.1.9. GlaxoSmithKline PLC
    • 12.1.10. Mitsubishi Tanabe Pharma Corporation
    • 12.1.11. Pfizer, Inc.
    • 12.1.12. Sandoz Inc. by Novartis AG
    • 12.1.13. Sun Pharmaceuticals Industries
    • 12.1.14. Taj Pharmaceuticals Ltd.
    • 12.1.15. Takeda Pharmaceuticals Company Limited
    • 12.1.16. Troikaa Pharmaceuticals Ltd.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing